Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

BioFocus extends collaboration with Usher III Initiative

BiofocusBioFocus has announced that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. 

BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a small-molecule therapy for Usher syndrome type III.  Under the terms of the extended agreement, BioFocus will further advance the project with the objective of delivering a pre-clinical candidate. 

"The extension of this collaboration is testament to the quality of the scientific input that BioFocus offers its clients," said Dr Chris Newton, Senior Vice President Galapagos Services.  "The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services."

"We are pleased with the progress BioFocus has made thus far on discovering potential therapies for Usher syndrome.  BioFocus' approach fits very well with our aim of getting therapies into the clinic quickly and efficiently," said Dr. David Saperstein, Scientific Director, Usher III Initiative, Inc. 

About Usher III Initiative, Inc.

The Usher III Initiative, Inc. is a non-profit organization dedicated to developing cures for blindness associated with Usher syndrome type III.  The Initiative funds research at universities and contract research organizations in the United States and Europe.  More info is available at:  www.usheriii.org

About BioFocus

BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery.  BioFocus' offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools.  As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries.  More info at: www.biofocus.com 


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners